Serum CXCL13 and galectin-9 were considered excellent for discriminating CLL patients and the controls with cut-off values ≥ 50 pg/mL and ≥ 412 pg/mL, respectively (p values < 0.0001). Here, CXCL13 is linked to B-cell chronic lymphocytic leukemia.